MedTrace Logo

DOAC in Unusual Site Venous Thrombosis

NCT03778502 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 358

Last updated 2025-07-03

No results posted yet for this study

Summary

Unusual site venous thromboembolism (VTE) refers to thrombosis occurring in venous districts outside the veins of the lower extremities and the pulmonary arteries, and includes splanchnic vein thrombosis (SVT), cerebral vein thrombosis (CVT), retinal vein thrombosis, ovarian vein thrombosis, and renal vein thrombosis. The use of the novel direct oral anticoagulants (DOAC), thrombin or factor Xa-inhibitors (such as dabigatran, apixaban, edoxaban, rivaroxaban), in patients with unusual VTE in clinical practice is increasing. Through an international multicentre prospective registry, the investigators aim to evaluate the rationale for the use of the DOAC for the treatment of unusual site VTE and to assess the safety and effectiveness of this approach in real life clinical practice.

Conditions

  • Splanchnic Vein Thrombosis
  • Cerebral Vein Thrombosis
  • Ovarian Vein Thrombosis
  • Renal Vein Thrombosis
  • Retinal Vein Thrombosis

Interventions

DRUG

Direct Oral Anticoagulants

Consecutive adult patients with objectively diagnosed unusual site venous thrombosis and treated with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban) will be eligible for this observational prospective registry

Sponsors & Collaborators

  • Università degli Studi dell'Insubria

    collaborator OTHER

  • University of Malta

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • United States
  • Canada
  • France
  • Israel
  • Italy
  • Malta
  • Netherlands
  • Slovenia
  • Spain
  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03778502 on ClinicalTrials.gov